Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer
- 1 December 2004
- journal article
- clinical trial
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 30 (10) , 1069-1076
- https://doi.org/10.1016/j.ejso.2004.07.024
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Accuracy of MRI in the Detection of Residual Breast Cancer After Neoadjuvant ChemotherapyAmerican Journal of Roentgenology, 2003
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Neoadjuvant Docetaxel in Locally Advanced Breast CancerBreast Cancer Research and Treatment, 2003
- Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cellWorld Journal of Gastroenterology, 2003
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18JNCI Monographs, 2001
- Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902Journal of Clinical Oncology, 2001
- Development, standardization, and testing of a lexicon for reporting contrast‐enhanced breast magnetic resonance imaging studiesJournal of Magnetic Resonance Imaging, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Technical Report of the International Working Group on Breast MRIJournal of Magnetic Resonance Imaging, 1999
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI Journal of the National Cancer Institute, 1990